期刊
THERAPEUTIC ADVANCES IN HEMATOLOGY
卷 7, 期 3, 页码 157-170出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/2040620716636542
关键词
B-cell receptor signaling inhibitors; chronic lymphocytic leukemia; entospletinib; idelalisib; lymphoid malignancies; phosphoinositide 3-kinase delta; spleen tyrosine kinase inhibitors
类别
The B-cell receptor signaling pathway has emerged as an important therapeutic target in chronic lymphocytic leukemia and other B-cell malignancies. Novel agents have been developed targeting the signaling enzymes spleen tyrosine kinase (SYK), Bruton's tyrosine kinase, and phosphoinositide 3-kinase delta. This review discusses the rationale for targeting these enzymes, as well as the preclinical and clinical evidence supporting their role as therapeutic targets, with a particular focus on SYK inhibition with entospletinib.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据